Recent Quotes

My Watchlist

Indicators

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY: ATNM )

1.290 +0.170 (+15.18%)

Official Closing Price Updated: 8:00 PM EST, Dec 20, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,084,004
Open	1.140
Bid (Size)	1.210 (5)
Ask (Size)	1.290 (1)
Prev. Close	1.120
Today's Range	1.125 - 1.290
52wk Range	1.100 - 10.24
Shares Outstanding	21,331,314
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

12 Health Care Stocks Moving In Friday's Pre-Market Session

October 25, 2024

Via Benzinga

Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

August 18, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Performance

YTD	-75.75%	-75.75%
1 Month	-12.24%	-12.24%
3 Month	-29.89%	-29.89%
6 Month	-82.75%	-82.75%
1 Year	-75.71%	-75.71%

More News

Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

August 09, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

August 07, 2024

From The Schall Law Firm

Via Business Wire

ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024

August 06, 2024

Via InvestorPlace

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

August 06, 2024

Via Benzinga

S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge

August 05, 2024

Via Benzinga

Dow Tumbles 950 Points; ISM Services PMI Surges In July

August 05, 2024

Via Benzinga

Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment

August 05, 2024

Via Benzinga

Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views

August 05, 2024

Via Benzinga

3 Under-$10 Biotech Stocks That Could Make You Rich

July 11, 2024

Via InvestorPlace

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

July 02, 2024

Via InvestorPlace

Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

June 18, 2024

Via Newsfile

Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

June 18, 2024

Via AB Newswire

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

Via FinancialNewsMedia

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

From FN Media Group LLC

Via GlobeNewswire

Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

June 17, 2024

Via FinancialNewsMedia

Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)

June 17, 2024

Via Newsfile

Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

June 17, 2024

Via FinancialNewsMedia

Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress

June 17, 2024

Via AB Newswire

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024

June 10, 2024

Via InvestorPlace

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

June 07, 2024

Via InvestorPlace

3 Cheap Biotech Stocks to Buy Now: May 2024

May 14, 2024

Via InvestorPlace

Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside

May 09, 2024

Via AB Newswire

Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions

May 08, 2024

Via AB Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.